Search - tctmd.com

Displaying 401 - 420 of 593

Sort: Relevancy | Date

Presentation TCT 2017

Debate: Making the Case for Not Pretreating ACS patients With Oral P2Y12 Receptor Inhibitors!

Presenter: John A. Bittl, Freek W.A. Verheugt, Somjot S. Brar

October 30, 2017

Presentation TCT 2017

Debate: Making the Case for Pretreating ACS patients With Oral P2Y12 Receptor Inhibitors!

Presenter: John A. Bittl, Freek W.A. Verheugt, Dimitrios Alexopoulos

October 30, 2017

Presentation TCT 2017

XIENCE Everolimus-Eluting Stents: Device Iterations, Randomized/Registry Outcomes Data in Perspective and the Move to Shorter DAPT

Presenter: Stephen G. Ellis, David E. Kandzari, Tullio Palmerini

October 30, 2017

Presentation TCT 2017

NSTEMI Case Presentation: Why the DAPT Pre-load Decision Matters

Presenter: John A. Bittl, Freek W.A. Verheugt, Patricia J. Best

October 30, 2017

Presentation TCT 2017

Should Choice of Parenteral Therapy for Primary PCI in STEMI Depend on Vascular Access?

Presenter: Michael S. Lee, Dirk Sibbing, John A. Bittl

October 30, 2017

Presentation TCT 2017

Parenteral Therapy in STEMI: Does VALIDATE Change the Equation?

Presenter: Michael S. Lee, Dirk Sibbing, David Erlinge

October 30, 2017

Presentation TCT 2017

Why I Use Cangrelor for Primary PCI in STEMI!

Presenter: Michael S. Lee, Dirk Sibbing, Dmitriy N. Feldman

October 30, 2017

Presentation TCT 2017

Why I Prefer Bivalirudin for Primary PCI in STEMI!

Presenter: Michael S. Lee, Dirk Sibbing, Uwe Zeymer

October 30, 2017

Presentation TCT 2017

Why I Prefer a Heparin Plus a GPI for Primary PCI in STEMI!

Presenter: Michael S. Lee, Dirk Sibbing, Eric R. Bates

October 30, 2017

$Why I Prefer Unfractionated Heparin Without GPI for Primary PCI in STEMI!$

Presentation TCT 2017

Why I Prefer Unfractionated Heparin Without GPI for Primary PCI in STEMI!

Presenter: Michael S. Lee, Dirk Sibbing, A. Michael Lincoff

October 30, 2017

Presentation TCT 2017

STEMI Case Presentation: Why the Choice of Patental Therapy Matters

Presenter: Michael S. Lee, Dirk Sibbing, Francesco Franchi

October 30, 2017

Presentation TCT 2017

Predicting The Future: Will the Ongoing DES 3-Month DAPT Studies With Synergy and Xience Change How We Treat High Risk Bleeding Patients?

Presenter: C. Michael Gibson, Stephan Windecker

October 30, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2017

Shelley Wood

October 29, 2017

Presentation TCT 2017

DAPT Duration: Individualized vs Generalized Approach

Presenter: Jeroen J. Bax, Michael A. Borger, Stephan Windecker, Marco Valgimigli

October 29, 2017

Presentation TCT 2017

Consideration of Prolonged DAPT After DES Deployment From Angioscopic Findings

Presenter: Takeshi Kimura, Shigeru Saito, Takafumi Ueno

October 29, 2017

Presentation

Lesion Complexity and Outcomes of Extended DAPT After PCI

October 23, 2017

News Daily News

Lesion Complexity and Patient Risk: A Balancing Act for DAPT Duration

Yael L. Maxwell

October 23, 2017

News Conference News TCT 2017

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

Shelley Wood

October 20, 2017

News Daily News

Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond

Michael O'Riordan

October 17, 2017

News Daily News

Bioresorbable Scaffolds Not to Be Chosen Over DES, Says European Task Force

Michael O'Riordan

October 11, 2017

Advertisement

Debate: Making the Case for Not Pretreating ACS patients With Oral P2Y12 Receptor Inhibitors!

Debate: Making the Case for Pretreating ACS patients With Oral P2Y12 Receptor Inhibitors!

XIENCE Everolimus-Eluting Stents: Device Iterations, Randomized/Registry Outcomes Data in Perspective and the Move to Shorter DAPT

NSTEMI Case Presentation: Why the DAPT Pre-load Decision Matters

Should Choice of Parenteral Therapy for Primary PCI in STEMI Depend on Vascular Access?

Parenteral Therapy in STEMI: Does VALIDATE Change the Equation?

Why I Use Cangrelor for Primary PCI in STEMI!

Why I Prefer Bivalirudin for Primary PCI in STEMI!

Why I Prefer a Heparin Plus a GPI for Primary PCI in STEMI!

Why I Prefer Unfractionated Heparin Without GPI for Primary PCI in STEMI!

STEMI Case Presentation: Why the Choice of Patental Therapy Matters

Predicting The Future: Will the Ongoing DES 3-Month DAPT Studies With Synergy and Xience Change How We Treat High Risk Bleeding Patients?

TCTMD’s Top 10 Most Popular Stories for October 2017

DAPT Duration: Individualized vs Generalized Approach

Consideration of Prolonged DAPT After DES Deployment From Angioscopic Findings

Lesion Complexity and Outcomes of Extended DAPT After PCI

Lesion Complexity and Patient Risk: A Balancing Act for DAPT Duration

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond

Bioresorbable Scaffolds Not to Be Chosen Over DES, Says European Task Force

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content